We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+27.41%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.58B
AUM Growth
-$40.8M
Cap. Flow
-$216M
Cap. Flow %
-8.36%
Top 10 Hldgs %
47.96%
Holding
78
New
7
Increased
10
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$33.1M
2
VTYX
Ventyx Biosciences
VTYX
+$30.2M
3
PEN icon
Penumbra
PEN
+$28.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$27.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$72.8M
3
ARGX icon
argenx
ARGX
+$39.2M
4
SKIN icon
SkinHealth Systems
SKIN
+$38.9M
5
CNC icon
Centene
CNC
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Consumer Staples 0.96%
3 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BVS icon
51
Bioventus
BVS
$799M
$9.09M 0.35%
1,299,139
-7,200
-0.6% -$56.4K
CUTR
52
DELISTED
Cutera, Inc.
CUTR
$8.87M 0.34%
+194,573
New +$8.87M
HUM icon
53
Humana
HUM
$46.7B
$8.23M 0.32%
+16,961
New +$8.25M
TOI icon
54
The Oncology Institute
TOI
$498M
$7.33M 0.28%
1,583,158
-152,958
-9% -$899K
ALXO icon
55
ALX Oncology
ALXO
$273M
$7.2M 0.28%
752,097
-14,700
-2% -$171K
NUVB icon
56
Nuvation Bio
NUVB
$2.24B
$6.79M 0.26%
3,031,009
-440,700
-13% -$1.26M
HOOK
57
DELISTED
HOOKIPA Pharma
HOOK
$6.11M 0.24%
456,225
– –
IVVD icon
58
Invivyd
IVVD
$180M
$6.01M 0.23%
1,920,960
– –
NVTA
59
DELISTED
Invitae Corporation
NVTA
$5.61M 0.22%
2,280,403
-1,525,000
-40% -$4.63M
SLGC
60
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$5.42M 0.21%
1,870,839
-217,800
-10% -$917K
ACHL
61
DELISTED
Achilles Therapeutics
ACHL
$3.63M 0.14%
1,608,089
– –
STXS icon
62
Stereotaxis
STXS
$129M
$2.68M 0.1%
1,487,495
– –
NGNE icon
63
Neurogene
NGNE
$696M
$2.2M 0.09%
171,847
– –
TCRR
64
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.97M 0.08%
1,094,645
– –
TKNO icon
65
Alpha Teknova
TKNO
$266M
$1.86M 0.07%
558,099
-9,701
-2% -$54.3K
XERS icon
66
Xeris Biopharma Holdings
XERS
$1.44B
$1.63M 0.06%
1,046,587
– –
BCEL
67
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$1.26M 0.05%
800,306
– –
SONX
68
DELISTED
Sonendo, Inc.
SONX
$533K 0.02%
498,131
– –
CABA icon
69
Cabaletta Bio
CABA
$439M
$453K 0.02%
696,377
– –
CTSO icon
70
Cytosorbents Corp
CTSO
$22.6M
$362K 0.01%
266,365
– –
BMRN icon
71
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-300,000
Closed -$24.9M
IMTX icon
72
Immatics
IMTX
$1.24B
– –
-449,661
Closed -$3.92M
PRVA icon
73
Privia Health
PRVA
$3.21B
– –
-206,113
Closed -$6M
TNDM icon
74
Tandem Diabetes Care
TNDM
$1.17B
– –
-187,460
Closed -$11.1M
NVRO
75
DELISTED
NEVRO CORP.
NVRO
– –
-405,517
Closed -$17.8M
1 2
3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q3 2022 Portfolio in Review

As of Q3 2022, Redmile Group held 78 positions worth $2.58B, down 1.6% from $2.62B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $216M in Q3 2022, closing 8 positions and reducing 27 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $151M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Stryker worth $31.9M.

  • Redmile Group's largest Q3 2022 buy was Stryker: 157,321 shares worth $31.9M.
  • Redmile Group added most to Pliant Therapeutics in Q3 2022, an estimated $27.5M increase.
  • Redmile Group's biggest Q3 2022 reduction was argenx, cutting an estimated $39.2M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $151M.
  • Redmile Group's ten largest holdings make up 48% of its $2.58B portfolio in Q3 2022.
  • Redmile Group opened 7 new positions and closed 8 in Q3 2022.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $2.58B.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.